Phase 2 Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who agree to and sign a consent form to take part in the trial
- People who have been diagnosed with Crohn's Disease for more than 6 months
- People who have at least one Crohn's Disease problem area that has not responded to standard medicines (such as azathioprine, 6-mercaptopurine, or methotrexate) or to biological treatments (such as anti-TNF therapies, vedolizumab, or ustekinumab)
- People whose treatment-resistant problem area is one of the following: a narrowing (stricture) of 2 to 5 cm in the colon or small intestine that can be reached by a colonoscopy camera; a deep, unhealed ulcer in the colon or small intestine reachable by colonoscopy; or one or more actively draining fistulas (abnormal tunnels) near the bottom/anal area
- The trial is enrolling specific groups: 20 people with narrowings (strictures), 20 people with deep unhealed ulcers, and 20 people with actively draining perianal fistulas
Who may not be able to join:
- People who need urgent bowel surgery right away
- People who have a blockage in their intestines
- People who have abnormal tunnels (fistulas) or a pocket of infection (abscess) inside the abdomen
- People whose narrowing or deep ulcer cannot be reached by a colonoscopy camera
- People who have an undrained abscess near the anal area
- People who are pregnant or planning to become pregnant within one year
- People who have a current bowel infection such as Clostridioides difficile or another identified infectious pathogen
- People with serious kidney problems (such as very low kidney function, dialysis, or inability to pass urine) or serious liver problems (such as cirrhosis, liver failure, hepatitis, bleeding from the oesophagus, fluid build-up in the abdomen, or chronic viral hepatitis with high bilirubin levels — confirm with trial site for full details)
- People with a confirmed HIV infection, or active hepatitis B, hepatitis C, or active tuberculosis
- People who have had a serious opportunistic infection within the past 6 months, or any serious infection within the past 3 months
- People who have had a cancer diagnosis within the past 5 years, or who have a history of a blood or lymph system cancer (lymphoproliferative disease)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Edouard Louis, Prof, Centre Hospitalier Universitaire de Liege
Phone: 043667256
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients with deep ulcer healing; Proportion of patients with stricture healing; Proportion of patients with complex perianal fistula healing; Safety assessed by the incidence of treatment-emergent adverse events during the study period
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.